ข่าวประชาสัมพันธ์ Eli Lilly and Company+Multiple Sclerosis

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. The data also showed

28 กรกฎาคม 2552 09:10 น.

Triastek announces research collaboration with Lilly to explore the application of 3D printing technology in oral delivery of drugs

On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to leverage the... ก.ค. 65

New Data Show Lilly's Once-Weekly Trulicity(R) (dulaglutide) Solution for Injection is Effective as Add-on Treatment to Sulfonylurea

Trulicity 1.5 mg Demonstrates Superior Efficacy in AWARD-8 Trial New data from a completed Phase 3 trial show Trulicity(R) (dulaglutide) solution for injection 1.5 mg... ธ.ค. 58

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab Patient-reported pain, joint stiffness, fatigue and physical... พ.ย. 58

European Commission Approves Trulicity(R) (dulaglutide) Solution for Injection, Lilly's Once-Weekly, Ready-to-Use Type 2 Diabetes Treatment

Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle... พ.ย. 57

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries

Significant portion of alliance opportunity will remain unchanged; some countries will transition to exclusive promotion in 2015 In a move that will strengthen their alliance by enhancing... ต.ค. 57

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

First biosimilar insulin to receive regulatory approval in the EU The European Commission (EC) granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's... ก.ย. 57

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

First biosimilar insulin to receive CHMP positive opinion in the EU The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the... มิ.ย. 57

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus(R)

Companies present comprehensive data for LY2963016, new insulin glargine product For the first time today, Eli Lilly and Company and Boehringer Ingelheim presented... มิ.ย. 57

Lilly and Alzheimer's Disease International Partner to Address Barriers that Impact the Accurate and Timely Diagnosis of Alzheimer's Disease

New educational resources to help patients and caregivers communicate vital information with physicians are released as global leaders meet to discuss the... มิ.ย. 57

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency Eli Lilly and Company and Boehringer Ingelheim today... ธ.ค. 56

Lilly Releases Report on Corporate Responsibility Efforts

Company communicates progress on numerous indicators of economic, environmental, and social performance Eli Lilly and Company (NYSE: LLY) has released its 2012-13 Corporate Responsibility Report [http://www.lilly.com/Documents/Lilly_2012_2013... ธ.ค. 56

Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes

Improvements in several indicators of diabetes management, including perceptions about hyperglycaemia and weight, observed for investigational GLP-1... ก.ย. 56

Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product

- European Medicines Agency accepted companies' marketing authorisation application Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the companies'... ก.ค. 56

Amyvid (Florbetapir (18F)) Solution for Injection Approved in European Union for Use in Patients with Cognitive Impairment Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Impairment

- Amyvid is the first and only PET imaging agent approved to measure beta-amyloid neuritic plaque ... ม.ค. 56

Lilly Reassumes Sole Worldwide Development and Commercialization Rights for Novel Basal Insulin Analog

- Announces it will begin remainder of pre-planned clinical trials for LY2605541 Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim International GmbH announced today they will adjust the... ม.ค. 56

ลิลลี่ เผยรายงานความคืบหน้าของการดำเนินการตามแนวทางความรับผิดชอบขององค์กร

บริษัทเปิดเผยถึงความคืบหน้าของปัจจัยบ่งชี้ทางเศรษฐกิจ สภาพแวดล้อม และการดำเนินการที่เกี่ยวกับสังคมหลายรายการ อิไล ลิลลี่ แอนด์ คอมพานี (Eli Lilly and Company) (NYSE: LLY) ได้เปิด... ธ.ค. 55

Lilly Releases Update on Corporate Responsibility Efforts

Company communicates progress on numerous indicators of economic, environmental and social performance Eli Lilly and Company (NYSE: LLY) has released its 2011/2012 Corporate Responsibility Update (www.lilly.com/Documents/Lilly_2011_2012... ธ.ค. 55

European Commission Approves Cialis for the Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia

- Cialis becomes the first and only medication approved in the EU for both the signs and symptoms of benign prostatic hyperplasia and erectile dysfunction Eli Lilly and Company (NYSE: LLY)... ต.ค. 55

ALIMTA(R) Label Update Approved by European Commission to Reflect Significant Overall Survival Benefits for Specific Lung Cancer Patients

Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved an update to the label for ALIMTA(R) (pemetrexed for injection), adding... ต.ค. 55

Amyvid (Florbetapir 18F) Solution for Injection Recommended for Approval in Europe as a Diagnostic Tool for Imaging Beta-Amyloid Plaques - a Common Neuropathological Feature of Alzheimer's Disease

- Milestone reflects Eli Lilly and Company's commitment to bring new diagnostic tool to physicians ... ต.ค. 55